Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 688

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 688
---
DENSED COMBINED FINANCIAL INFORMATIONBRepresents the $250,000 of additional financing received on January 5, 2025, as well as an additional $500,000 of financing which is expected to be received in two separate installments prior to the Closing of the Mergers, that are presented as both cash inflows (for Kineta) and cash outflows (for TuHURA), for an aggregate amount of $750,000 of subsequent financings that are directly attributable to the Mergers. These payments reflect the working capital loans detailed in the provisions of the Merger Agreement which provides that Kineta may request the extension of additional working capital loans from TuHURA in increments of $250,000 on dates specified within the Merger Agreement; the last of which is to be advanced by TuHURA to Kineta on or before June 3, 2025, with that amount being contingent upon TuHURA’s receipt of (A) proceeds from the Concurrent Investment or (B) proceeds from TuHURA’s stockholder warrant exercise payments due on May 30, 2025. As TuHURA’s stockholder warrant exercise payments are expected to be received in advance of their maturity date (reflected in AdjustmentD) in addition to the receipt of the Concurrent Investment by TuHURA in advance of the Closing Date (reflected in AdjustmentC), the final $250,000 working capital loan included in the Merger Agreement is accordingly reflected within this pro forma adjustment.The unaudited pro forma condensed combined balance sheet as of December 31, 2024 includes these adjustments to give pro forma effect for both the cash loaned by TuHURA and received by Kineta subsequent to December 31, 2024, to illustrate the funding provided by TuHURA which, under the terms of the Merger Agreement, allows for all such loaned amounts between the parties to be credited against the cash component of the Merger Consideration to be paid to Kineta stockholders in the Mergers (refer to AdjustmentE).CRelating to the Mergers, to record proceeds received of $18,400,000 after taking into account $1,600,000 (comprised of an estimated $1,200,000 of placement fees and an additional $400,000 in legal fees), following the issuance, through a Concurrent Investment to be consummated prior to the Closing of the Mergers, of approximately 4,952,579 shares of Tu